(Q39378798)

11 September 2017

title

Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease (English)

1 reference

11 September 2017

0 references

0 references

P Bytzer

1

1 reference

11 September 2017

A Blum

2

1 reference

11 September 2017

D De Herdt

3

1 reference

11 September 2017

D Dubois

4

1 reference

11 September 2017

Trial Investigators

5

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Alimentary Pharmacology & Therapeutics

11 September 2017

published in

1 reference

11 September 2017

volume

20

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

181-188

1 reference

Nonerosive reflux disease--current concepts and dilemmas

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

Review article: rabeprazole's tolerability profile in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01999.X

10.1111/J.1365-2036.2004.01999.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference